BioCryst Pharmaceuticals (NASDAQ:BCRX) Now Covered by Evercore

Evercore assumed coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report released on Wednesday morning. The firm issued an outperform rating and a $17.00 target price on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the stock. Needham & Company LLC dropped their target price on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th. Royal Bank Of Canada decreased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. Barclays cut their target price on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 4th. Zacks Research downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Finally, HC Wainwright lifted their price target on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.64.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $7.26 on Wednesday. The firm has a market cap of $1.53 billion, a P/E ratio of -145.20 and a beta of 0.83. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.31. The business’s fifty day moving average is $7.10 and its 200-day moving average is $7.42.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 21,773 shares of the stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.65, for a total value of $166,563.45. Following the completion of the transaction, the insider directly owned 398,751 shares in the company, valued at approximately $3,050,445.15. This trade represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders sold 183,453 shares of company stock worth $1,330,965. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BCRX. Larson Financial Group LLC grew its holdings in BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,267 shares during the last quarter. Focus Partners Wealth acquired a new position in shares of BioCryst Pharmaceuticals during the third quarter worth $77,000. Farther Finance Advisors LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 326.8% during the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 8,109 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the last quarter. Finally, Vestmark Advisory Solutions Inc. bought a new position in BioCryst Pharmaceuticals during the 3rd quarter worth $81,000. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.